Analysis of outcome of 6-month readmissions after percutaneous left atrial appendage occlusion

Heart ◽  
2021 ◽  
pp. heartjnl-2021-319345
Author(s):  
Sae Morita ◽  
Aaqib H Malik ◽  
Toshiki Kuno ◽  
Tomo Ando ◽  
Risheek Kaul ◽  
...  

ObjectivePercutaneous left atrial appendage occlusion (LAAO) is an alternative strategy for prevention of thromboembolic events in patients with atrial fibrillation and unsuitable for long-term oral anticoagulation. The study aimed to evaluate the causes and timing of readmissions within 6 months following percutaneous LAAO in a real-world setting.MethodsWe conducted a retrospective cohort study of percutaneous LAAO performed in the USA between January and June of 2016–2018 using the Nationwide Readmissions Database.ResultsOverall, 12 446 patients who underwent LAAO were included in the analyses and 3477 patients (28%) were readmitted within 6 months following the interventions. Readmitted patients were more often women (p=0.001). The index hospitalisation was characterised by longer duration of hospital stay (p<0.001) and complicated with acute kidney injury (p<0.001) among readmitted patients compared with those without readmissions. Readmissions within 6 months following the index intervention were mainly due to heart failure (13%) and gastrointestinal bleeding (12%). Characteristics associated with readmissions due to heart failure included previously known heart failure (HR 2.39; 95% CI 1.70 to 3.37), valvular heart disease (HR 1.39; 95% CI 1.05 to 1.84) and chronic kidney disease (HR 1.42; 95% CI 1.03 to 1.94). Readmissions due to gastrointestinal bleeding were associated with diabetes mellitus (HR 1.78; 95% CI 1.25 to 2.53), chronic kidney disease (HR 1.86; 95% CI 1.23 to 2.81) and previous anaemia (HR 2.41; 95% CI 1.54 to 3.77).ConclusionsAfter percutaneous LAAO, over a quarter of the patients in the USA required rehospitalisation within 6 months, mainly due to heart failure and gastrointestinal bleeding.

2020 ◽  
Vol 4 (1) ◽  
pp. 1-5
Author(s):  
Andre Briosa e Gala ◽  
Andrew Cox ◽  
Michael Pope ◽  
Timothy Betts

Abstract Background Caring for athletes with cardiac disease requires an approach that caters to the specific needs of the athlete. Case summary A 27-year-old professional rugby player was admitted with decompensated heart failure and atrial fibrillation (AF). Transthoracic echocardiogram showed features in keeping with a dilated cardiomyopathy with severe left ventricular (LV) systolic impairment. He made good progress on evidence-based heart failure medication and his LV systolic function returned to normal. He failed to maintain sinus rhythm with cardioversion and remained in persistent AF. He then suffered a transient ischaemic attack despite appropriate anticoagulation. At 1-year follow-up, he was asymptomatic and against medical advice continued to play competitive rugby whilst taking rivaroxaban. He subsequently underwent implantation with a percutaneous left atrial appendage occlusion device, allowing him to discontinue anticoagulation, reduce his bleeding risk and resume his career, whilst simultaneously lowering the thromboembolic risk. Discussion Counselling should include different management options aimed at minimizing the risks to athletes if they to return to competitive sports. Left atrial appendage occlusion devices are a suitable AF-related stroke prevention strategy in athletes competing in full-contact sports.


2021 ◽  
Vol 25 (07) ◽  
pp. 273-278
Author(s):  
Boris Schmidt ◽  
Kyrill Rogacev

ZUSAMMENFASSUNGBedauerlicherweise existieren bisher keine randomisierten Studiendaten hinsichtlich des Stellenwerts eines Vorhofohrverschlusssystems (LAAC: „left atrial appendage closure“) im Vergleich zu oralen Antikoagulanzien (OAK) bei CKD-Patienten (CKD: „chronic kidney disease“). Eine derartige Studie (WATCH AFIB in CKD) wurde wegen geringer Rekrutierungszahlen eingestellt. Aus den im Beitrag angesprochenen Beobachtungsstudien kann allerdings eine gute Sicherheit und Effektivität der Therapie abgeleitet werden. In Anbetracht der unzureichenden Evidenz sollte bei VHF Patienten (VHF: Vorhofflimmern) mit CKD bis zu einer glomerulären Filtrationsrate (GFR) von 30 ml/min/1,73 m2 primär eine NOAK-Therapie (NOAK: neue OAK) verordnet werden. Im Falle von Blutungen kann dann gemäß Leitlinienempfehlung eine LAAC alternativ angeboten werden. Im Falle von Patienten mit dialysepflichtiger CKD muss eine individuelle Entscheidung getroffen werden, ob und wie eine Thromboembolieprophylaxe durchgeführt werden soll.


Sign in / Sign up

Export Citation Format

Share Document